European physicians want more information in the biosimilar label than is currently available, according to a new study initiated and supported by EuropaBio.
When comparing a standard label of an authorized biosimilar with a label containing additional relevant information, 83% of physicians preferred the one with additional information about what data had been generated with which product, according to a press release.
In addition, 91% said that they use the label frequently or occasionally as a source of information and 87% said it was helpful, or very helpful, to include a clear statement on the origin of the biosimilar’s data on the label.
In the European Union, labels of biosimilars and their reference products are in many instances almost identical, despite different data requirements.
